Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.33 -0.37 (-1.39%)

Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

3 Monster Dividend Stocks to Hold for the Next 10 Years ↗

April 02, 2026

These are great and steady income providers for your portfolio.

Via The Motley Fool

Pfizer, BioNTech Hit Pause On COVID Shot Trial As Enrollment Falls Flat ↗

April 01, 2026

Pfizer & BioNTech halt recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment. Read the latest updates.

Via Benzinga

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges ↗

April 01, 2026

The company said its prostate cancer drug showed comparable effectiveness to a rival in the class.

Via Investor's Business Daily

Which S&P500 stocks are the most active on Tuesday? ↗

March 31, 2026

Via Chartmill

Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout ↗

March 20, 2026

Via Chartmill

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗

March 29, 2026

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Via The Motley Fool

Topics Intellectual Property

1 Reason This Biotech Stock Could Triple Before Year-End ↗

March 29, 2026

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Via The Motley Fool

Is Now the Time to Buy Salesforce? Here's What the Numbers Reveal ↗

March 28, 2026

Salesforce's numbers seem to add up to the stock being a solid pick.

Via The Motley Fool

Topics Artificial Intelligence

Could Buying Eli Lilly Today Set You Up for Life? ↗

March 26, 2026

Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.

Via The Motley Fool

Topics Intellectual Property

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

Is Pfizer Stock a Buy After This Win? ↗

March 25, 2026

Good news has been scarce for this beaten-down drugmaker.

Via The Motley Fool

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

March 25, 2026

As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its...

Via Finterra

Topics Economy Intellectual Property Retirement

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Stay informed about the most active stocks in the S&P500 index on Tuesday's session. ↗

March 24, 2026

Via Chartmill

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

March 24, 2026

From Pfizer Inc.

Via Business Wire

Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 24, 2026

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.

Via Benzinga

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Pfizer Stock Is Doing Something It Hasn't Done Since 2022 ↗

March 23, 2026

Up until recently, the stock has been a chronic underperformer.

Via The Motley Fool

Topics Economy Intellectual Property

5 High-Yield Stocks to Shield Your Portfolio From the Storm ↗

March 23, 2026

Via MarketBeat

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive ↗

March 23, 2026

Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions.

Via Benzinga

Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 23, 2026

Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down.

Via Benzinga

Topics Stocks

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

March 23, 2026

From Pfizer Inc.

Via Business Wire

Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now ↗

March 23, 2026

You can get in on these market giants for bargain prices today.

Via The Motley Fool

Topics Intellectual Property

March 23, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Topics Supply Chain

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

March 20, 2026

From Pfizer Inc.

Via Business Wire

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗

March 19, 2026

They aren't just "pandemic stocks."

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.